Drug General Information
Drug ID	D0O3OI
Former ID	DIB004165
Drug Name	AVL-3288
Indication	Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3]		Phase 1	[524285]
Company	Anvyl pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Neuronal acetylcholine receptor protein, alpha-7 chain	Target Info	Modulator	[531708]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Cholinergic synapse
	Nicotine addiction
	Chemical carcinogenesis
PANTHER Pathway	Alzheimer disease-amyloid secretase pathway
	Nicotinic acetylcholine receptor signaling pathway
Reactome	Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
WikiPathways	SIDS Susceptibility Pathways
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
References
Ref 524285	ClinicalTrials.gov (NCT01851603) Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects. U.S. National Institutes of Health.
Ref 531708	Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.